{
    "2021-06-29": [
        [
            {
                "time": "2023-10-10",
                "original_text": "Upadacitinib (RINVOQ®) Met the Primary and All Secondary Endpoints in the 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients",
                "features": {
                    "keywords": [
                        "Upadacitinib",
                        "RINVOQ®",
                        "Phase 3",
                        "Ulcerative Colitis",
                        "Endpoints",
                        "Maintenance Study"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}